Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

Abstract

Objective-High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years.Methods-A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and lowgrade serous subtypes were excluded.Results-The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Disclosures/Conflicts of InterestThe authors declare no competing financial interests. HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of less than 12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis.Conclusions-LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes.

Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium

“…This, in conjunction with data showing worse outcomes for high‐grade serous tumors compared to other types, suggests that some tumors may be intrinsically more aggressive than others. While differences in survival across tumor subtypes can be explained, in part, by surgical outcomes, a recent study noted that changes in chemotherapy regimens did not substantially influence long‐term survival . More recently, studies have shown that exposures before diagnosis are differently associated with ovarian cancer subtypes, with each histologic type showing a distinct pattern of risk factor associations .…”

Morphology and tumour‐infiltrating lymphocytes in high‐stage, high‐grade serous ovarian carcinoma correlated with long‐term survival

“…Dao et al ., in a multi‐centre study, described 203 patients with HGSC who survived more than 10 years, 72.4% of whom had FIGO IIIc disease initially. Eighty‐eight patients (46.8%) remained recurrence‐free after a median follow‐up of 144 months . A study of the California Cancer Registry on 11 541 ovarian cancer patients among all histological subtypes and stages identified a total of 3583 patients (31%) who survived more than 10 years and, of these, 32.4% had stage III/IV disease.…”

Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non‐invasive malignant serous ovarian tumors

“…HGSCs are generally symptomatic and present at an advanced stage, and only 2% of HGSC cases are diagnosed at FIGO Stage I. In patients with advanced disease, the most important predictor of survival is complete surgical resection of all visible disease.…”